Skip to content

What is Trulicity (dulaglutide)? Uses, doses, cost and side effects

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

What is Trulicity? It's dulaglutide, a once-weekly injection from Eli Lilly. It's approved to improve blood sugar control in adults and children 10 and older with type 2 diabetes, and to reduce major cardiovascular events in adults with type 2 diabetes and cardiovascular disease or risk factors. Self-pay starts at $389 a month through LillyDirect.

Source: LillyDirect self-pay

Key takeaways

  • Trulicity is a weekly injection for type 2 diabetes. It isn't approved for weight management.
  • Paying cash? LillyDirect self-pay starts at $389 a month, the same at every strength.
  • Missed a dose? Take it if at least 3 days remain until your next dose. Otherwise skip it.
  • If needed, a pen can stay at room temperature, not above 86°F (30°C), for a total of 14 days.
  • Medicare Part D can cover it for type 2 diabetes, but it isn't part of the Medicare GLP-1 Bridge.

Trulicity at a glance

Trulicity facts from the FDA label and verified prices
Active ingredientdulaglutide
MakerEli Lilly and Company
FDA-approved uses
  • adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus
  • reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors
Forms and strengths
  • Single-dose pen: 0.75, 1.5, 3, 4.5 mg
Medicare GLP-1 BridgeNot in the Bridge
Cheapest verified self-pay$389 per fill at 4.5 mg, LillyDirect self-pay (lilly.com)
With commercial insurance that covers it$389 per fill at 4.5 mg, LillyDirect self-pay (lilly.com)
LabelRevised: 3/2026 (DailyMed version 62)

Trulicity dose schedule from the label

Put it on a calendar with the titration schedule builder. Only your prescriber decides when, and whether, your dose changes.

See every price

Every verified Trulicity price

Trulicity: price by where you buy, form and dose
Where you buyForm · dosePriceConditionsSource
LillyDirect self-paySingle-dose pen · All strengths$389/month
Conditions

Self-pay only through LillyDirect; the same $389/month starting price is shown for every strength (0.75, 1.5, 3 and 4.5 mg). Prescription required; additional taxes and fees may apply; purchase terms apply.

lilly.com
List priceSingle-dose pen · All strengths$1,006.93/month
Conditions

List price (WAC) per month; a monthly supply is four pens.

pricinginfo.lilly.com

Trulicity is Eli Lilly’s brand of dulaglutide, a GLP-1 medicine for type 2 diabetes that you inject once a week from a single-dose pen. Most people have practical questions: what it costs, how the doses step up, and what to do when you miss a dose. This guide answers them from the FDA label (Revised: 3/2026 (DailyMed version 62)) and from the prices Lilly publishes.

What is Trulicity approved for?

Trulicity has two approved uses:

  • Type 2 diabetes. Along with diet and exercise, to improve blood sugar (glycemic) control in adults and in children 10 years of age and older with type 2 diabetes.
  • Cardiovascular risk. To reduce the risk of major adverse cardiovascular events (serious heart and blood vessel problems) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.

Trulicity’s label doesn’t include weight management. Its safety and effectiveness haven’t been established in children under 10. It isn’t recommended if you have severe gastroparesis (a condition where the stomach empties very slowly). The label also advises caution in people with liver impairment, because clinical experience in that group is limited.

What the trials showed

The label reports each trial separately. HbA1c (A1c) is a blood test of average blood sugar over recent months, and these figures are the change from the start of the trial.

  • Trulicity alone (26 weeks). A1c changed by -0.7 on 0.75 mg and -0.8 on 1.5 mg, compared with -0.6 on metformin.
  • Added to metformin (26 weeks). A1c changed by -1.0% on 0.75 mg and -1.2% on 1.5 mg, compared with 0.1% on placebo and -0.6% on sitagliptin. Mean (average) weight reduction was 2.7 kg and 3.0 kg on the two Trulicity doses, versus 1.4 kg on placebo.
  • Higher doses, added to metformin (36 weeks). A1c changed by -1.5 on 1.5 mg, -1.6 on 3 mg and -1.8 on 4.5 mg. Body weight changed by -3.0 kg, -3.8 kg and -4.6 kg.

In the REWIND cardiovascular outcomes trial (median follow-up 5.4 years), Trulicity 1.5 mg reduced the risk of a first event of cardiovascular death, non-fatal heart attack or non-fatal stroke compared with placebo, with a hazard ratio of 0.88 (95% CI 0.79 to 0.99). A hazard ratio compares risk between two groups, and the CI, or confidence interval, is the range the true figure likely falls in.

These are group averages. Your own A1c target and the dose that gets you there are decisions for you and your prescriber.

What form does Trulicity come in?

Trulicity comes in one form: a single-dose pen. Each pen holds one weekly dose in 0.5 mL, and you throw it away after use. A carton contains four pens, which is a 28-day supply. There’s no vial, no multi-dose pen and no dial to set.

The four pens differ only in strength: 0.75 mg, 1.5 mg, 3 mg, 4.5 mg.

The label says patients and caregivers should be trained on proper injection technique before starting, and that a healthcare provider should show you how to use the pen before the first time. Put used pens in an FDA-cleared sharps disposal container straight after use, not in household trash.

How much does Trulicity cost?

Lilly publishes two prices for Trulicity:

  • List price: $1,006.93 per month (four pens). What you actually pay largely depends on your insurance plan.
  • LillyDirect self-pay: starting at $389 a month. Lilly shows the same starting price for every strength, from 0.75 mg to 4.5 mg. This is a cash price if you’re not using insurance. You need a prescription, and taxes and fees may be added.

The self-pay price is the same at each strength, so stepping up the dose doesn’t raise your monthly cost on that route. A fill covers 28 days, so a year is 13 fills, which comes to $5,057 at the LillyDirect starting price.

If you have commercial insurance, ask your pharmacist whether a manufacturer copay offer applies to you, and read its terms before you rely on it.

Our Trulicity cost guide covers the routes in more depth, and the cost calculator will price a year for you. If you’re paying cash for any GLP-1, the guide to paying without insurance compares the self-pay programs.

What doses does Trulicity come in?

Trulicity comes in 0.75 mg, 1.5 mg, 3 mg, 4.5 mg, each given once weekly. The label’s schedule is:

  1. Start at 0.75 mg once weekly.
  2. After 4 weeks, the dose may go up to 1.5 mg once weekly for more blood sugar control.
  3. If you still need more control, the dose goes up in 1.5 mg steps (to 3 mg, then 4.5 mg), each after at least 4 weeks on the current dose.

The maximum recommended dose is 4.5 mg once weekly in adults. For children 10 and older, the maximum is 1.5 mg once weekly.

Unlike some newer GLP-1 medicines, Trulicity’s starting dose is also a dose you can stay on. The label says the dose may be increased, not that it must be. The dose ladder on this page shows the steps, and the titration schedule tool sets them against dates. (Titration means stepping a dose up slowly.)

How do you take Trulicity?

Inject Trulicity under the skin of your abdomen, thigh or upper arm, and rotate the site with each dose. You can take it at any time of day, with or without food. The Medication Guide says to use it once a week, on the same day each week.

Check the pen before use. The medicine should look clear and colorless. The label says not to use it if you see particles or color.

If you also use insulin, give the two as separate injections and never mix them. The label says you can inject them in the same body region, but not right next to each other.

What if I miss a dose of Trulicity?

Trulicity’s rule is different from those of other weekly GLP-1 injections, so read it closely. It counts the days until your next scheduled dose, not the days since the one you missed:

  • If there are at least 3 days (72 hours) until the next scheduled dose, take the missed dose as soon as possible.
  • If less than 3 days remain before the next scheduled dose, skip the missed dose and take the next dose on your regular day.

Either way, you then go back to your regular once-weekly schedule.

Here’s an example. Say your day is Sunday and you remember on Wednesday. Sunday is still four days away, so the label’s instruction is to take the dose. If you remember on Friday, less than three days remain, so the label’s instruction is to skip it and inject on Sunday as usual.

You can also move your weekly day if you need to, as long as your last dose was given 3 or more days before the new day.

The missed dose tool applies these rules to your own dates. If you’ve missed more than one dose, ask your prescriber how to resume.

What are the side effects of Trulicity?

Stomach and bowel effects are the most common. In the label’s pool of placebo-controlled trials in adults with type 2 diabetes (0.75 mg and 1.5 mg doses), gastrointestinal reactions occurred in 32 percent of people on 0.75 mg and 41 percent on 1.5 mg, compared with 21 percent on placebo. By reaction, on 0.75 mg and 1.5 mg versus placebo:

  • Nausea: 12.4 and 21.1 percent, versus 5.3 percent.
  • Diarrhea: 8.9 and 12.6 percent, versus 6.7 percent.
  • Vomiting: 6.0 and 12.7 percent, versus 2.3 percent.
  • Abdominal pain: 6.5 and 9.4 percent, versus 4.9 percent.
  • Decreased appetite: 4.9 and 8.6 percent, versus 1.6 percent.

More people stopped treatment because of gastrointestinal reactions on Trulicity (1.3 percent on 0.75 mg and 3.5 percent on 1.5 mg) than on placebo (0.2 percent).

For the higher doses, the label reports a separate 36-week trial with no placebo group. Nausea was reported by 13.4 percent on 1.5 mg, 15.6 percent on 3 mg and 16.4 percent on 4.5 mg. Vomiting was reported by 5.6, 8.3 and 9.3 percent. Both tables are shown in full on this page.

Low blood sugar

The label warns that using Trulicity with insulin or with a sulfonylurea may raise the risk of low blood sugar, including severe low blood sugar. In a 78-week trial, hypoglycemia (glucose below 54 mg/dL) occurred in 20% of patients on Trulicity 0.75 mg and 21% on 1.5 mg when it was given with a sulfonylurea. The label says your prescriber should consider reducing the dose of the sulfonylurea or insulin when you start Trulicity.

The boxed warning: thyroid C-cell tumors

Trulicity carries a boxed warning, the FDA’s strongest. In male and female rats, dulaglutide caused an increase in thyroid C-cell tumors after lifetime exposure. It’s not known whether Trulicity causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in people.

For that reason, Trulicity is contraindicated, meaning it must not be used, in anyone with a personal or family history of MTC, or with multiple endocrine neoplasia syndrome type 2 (MEN 2). It’s also contraindicated in anyone who has had a serious hypersensitivity (allergic) reaction to dulaglutide or any of the product’s components.

Other warnings on the label

The label also warns about acute pancreatitis, serious allergic reactions, acute kidney injury from dehydration after vomiting or diarrhea, severe gastrointestinal reactions, diabetic retinopathy complications in people with a history of retinopathy, acute gallbladder disease, and pulmonary aspiration (stomach contents entering the lungs) during general anesthesia or deep sedation. Tell any clinician planning a procedure that you take Trulicity.

Two more points:

  • Other medicines taken by mouth. Trulicity slows stomach emptying, which can reduce how quickly oral medicines are absorbed. The label says drug levels of oral medicines with a narrow therapeutic index (where small dose changes matter a lot), such as warfarin, should be monitored when taken with Trulicity.
  • Pregnancy. Trulicity should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

How do I store Trulicity?

Store Trulicity in the refrigerator at 36°F to 46°F (2°C to 8°C). Keep it in the original carton until you use it, to protect it from light. Don’t freeze it, and don’t use a pen that has been frozen.

If needed, you can keep each single-dose pen at room temperature, not above 86°F (30°C), for a total of 14 days. That allowance is shorter than for some other weekly pens, which matters when you travel or when a delivery sits outside. If you’re unsure whether a pen is still usable, ask your pharmacist before injecting.

Does insurance or Medicare cover Trulicity?

Commercial insurance

As a diabetes medicine, Trulicity is listed by many commercial plans, sometimes with conditions such as prior authorization (the plan’s approval before it pays) or trying another medicine first. Plans differ, so call the number on your insurance card. Ask whether Trulicity is on the formulary (the plan’s list of covered drugs), which tier it sits on, and what your prescriber needs to send. If a request is denied, the appeal letter generator drafts a letter your prescriber can adapt.

Medicare

CMS, the federal Medicare agency, states that type 2 diabetes is an indication eligible for Part D coverage, and that people with a GLP-1 prescription for a Part D covered use should keep getting it through their Part D plan. For Trulicity, that means coverage runs through your plan’s formulary, and the plan sets your share of the cost.

Trulicity isn’t part of the Medicare GLP-1 Bridge. That temporary program covers certain medicines for weight management, and people with type 2 diabetes aren’t eligible for it. Our Medicare hub explains how the pieces fit.

How Trulicity compares with other GLP-1 medicines for type 2 diabetes

Trulicity is one of several GLP-1 medicines approved for type 2 diabetes. Ozempic (semaglutide) is another weekly injection, Rybelsus is a daily semaglutide tablet, and Mounjaro (tirzepatide) is a weekly injection from the same manufacturer as Trulicity.

One head-to-head result involving Trulicity appears on a label. In Mounjaro’s cardiovascular outcomes trial (median follow-up 210.1 weeks), Mounjaro was non-inferior to dulaglutide for major cardiovascular events, with a hazard ratio of 0.92. Non-inferior means it was shown to be not worse by a set margin. Superiority to dulaglutide wasn’t established. Beyond that, the trials on each label were run separately with different patients, so you can’t rank their numbers against each other.

On practical points, Trulicity comes only as a single-dose pen with nothing to dial, and its self-pay starting price is the same at every strength. If your prescriber is moving you between medicines, the switching planner shows what each label says about where to start. It doesn’t convert doses from one drug to another.

Where the facts on this page come from

We take each price from the manufacturer’s own page, in the wording that page uses, by the method described in how we verify prices. Label facts come from the FDA label for Trulicity. The same prices feed the GLP-1 Price Index.

Where to get Trulicity

Some links on this page are affiliate links: if you sign up through them we may earn a commission at no extra cost to you. The cheapest legitimate option is always listed first, and payouts never affect rankings. How we make money.

  1. 1. LillyDirect self-pay

    $389 per fill at 4.5 mg

    Single-dose pen

    Source: lilly.comGo to the program page

Ranked by cost only. Manufacturer and government programs never pay us. To see every option for your situation, try the cheapest-path quiz.

Frequently asked questions

What is Trulicity used for?

Trulicity has two FDA-approved uses. Along with diet and exercise, it improves blood sugar control in adults and children 10 years and older with type 2 diabetes. It's also approved to reduce the risk of major adverse cardiovascular events (serious heart and blood vessel problems) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.

How much does Trulicity cost?

Trulicity's list price is $1,006.93 per month, which is four pens. If you pay cash through LillyDirect, it starts at $389 a month, and that starting price is shown for every strength. What you pay with insurance depends on your plan.

Is Trulicity approved for weight loss?

No. Trulicity's label doesn't include weight management. Its two approved uses are blood sugar control in type 2 diabetes and lowering cardiovascular risk in adults with type 2 diabetes. In one trial on the label, where Trulicity was added to metformin, mean (average) weight reduction was 2.7 kg and 3.0 kg on the two Trulicity doses, versus 1.4 kg on placebo.

What doses does Trulicity come in?

Trulicity comes in four single-dose pens: 0.75 mg, 1.5 mg, 3 mg, 4.5 mg. The label starts at 0.75 mg once weekly. After 4 weeks the dose may go up to 1.5 mg for more blood sugar control, and then in 1.5 mg steps, each after at least 4 weeks. The maximum recommended adult dose is 4.5 mg once weekly.

What should I do if I miss a dose of Trulicity?

The label's rule looks ahead to your next dose. If there are at least 3 days (72 hours) until the next scheduled dose, take the missed dose as soon as possible. If less than 3 days remain, the label says to skip the missed dose and take the next one on your regular day. Then continue your usual weekly schedule.

Can I change the day I take Trulicity?

Yes. The label says you can change the day of weekly use if necessary, as long as your last dose was given 3 or more days before the new day. Otherwise, the Medication Guide tells you to use Trulicity once a week on the same day each week, at any time of day.

How long can Trulicity stay out of the fridge?

Store Trulicity in the refrigerator at 36°F to 46°F (2°C to 8°C). If needed, you can keep each single-dose pen at room temperature, not above 86°F (30°C), for a total of 14 days. Don't freeze it, and don't use a pen that has been frozen.

What are the most common side effects of Trulicity?

In the label's pooled placebo-controlled trials, the most common reactions were nausea, diarrhea, vomiting, abdominal pain, decreased appetite, dyspepsia (indigestion) and fatigue. Nausea was reported by 12.4 percent of people on 0.75 mg and 21.1 percent on 1.5 mg, compared with 5.3 percent on placebo. Trulicity also carries a boxed warning about thyroid C-cell tumors.

Does Medicare cover Trulicity?

Type 2 diabetes is a use that Medicare Part D can cover, so Trulicity coverage runs through your Part D plan and its formulary, and your cost depends on the plan. Trulicity isn't one of the drugs in the Medicare GLP-1 Bridge. That's a temporary program for weight management, and it isn't open to people with type 2 diabetes.

Sources (34)

  1. 1.
    FDA label (DailyMed): Trulicity prescribing information, section 2.4
    “Inject TRULICITY subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites with each dose.”
  2. 2.
    FDA label (DailyMed): Trulicity prescribing information, section 2.4
    “Administer TRULICITY once weekly, any time of day, with or without food.”
  3. 3.
    FDA label (DailyMed): Trulicity Medication Guide (in the prescribing information)
    “Use TRULICITY 1 time each week on the same day each week at any time of the day.”
  4. 4.
    FDA label (DailyMed): Trulicity prescribing information, section 2.4
    “Prior to initiation, train patients and caregivers on proper injection technique [see Instructions for Use].”
  5. 5.
    FDA label (DailyMed): Trulicity Medication Guide (in the prescribing information)
    “Your healthcare provider should show you how to use TRULICITY before you use it for the first time.”
  6. 6.
    FDA label (DailyMed): Trulicity prescribing information, section 2.4
    “Inspect TRULICITY visually before use. It should appear clear and colorless. Do not use TRULICITY if particulate matter or coloration is seen.”
  7. 7.
    FDA label (DailyMed): Trulicity prescribing information, section 2.4
    “When using TRULICITY with insulin, administer as separate injections and never mix. It is acceptable to inject TRULICITY and insulin in the same body region, but the injections should not be adjacent to each other.”
  8. 8.
    FDA label (DailyMed): Trulicity prescribing information, section 2.1
    “The maximum recommended dosage is 4.5 mg injected subcutaneously once weekly.”
  9. 9.
    FDA label (DailyMed): Trulicity prescribing information, section 16.2
    “Store TRULICITY in the refrigerator at 36°F to 46°F (2°C to 8°C).”
  10. 10.
    FDA label (DailyMed): Trulicity prescribing information, section 16.2
    “If needed, each single-dose pen can be kept at room temperature, not to exceed 86°F (30°C) for a total of 14 days.”
  11. 11.
    FDA label (DailyMed): Trulicity prescribing information, section 16.2
    “Do not freeze TRULICITY. Do not use TRULICITY if it has been frozen.”
  12. 12.
    FDA label (DailyMed): Trulicity prescribing information, section 16.2
    “Protect TRULICITY from light. Storage of TRULICITY in the original carton is recommended until time of administration.”
  13. 13.
    FDA label (DailyMed): Trulicity Instructions for Use (in the prescribing information)
    “Put your used Pens in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) Pens in your household trash.”
  14. 14.
    FDA label (DailyMed): Trulicity prescribing information, section 8.1
    “TRULICITY should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”
  15. 15.
    FDA label (DailyMed): Trulicity prescribing information, section 7.2
    “When initiating TRULICITY, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions (5.3) and Adverse Reactions (6.1)].”
  16. 16.
    FDA label (DailyMed): Trulicity prescribing information, section 6.1
    “In a 78-week adult clinical trial, hypoglycemia (glucose level <54 mg/dL) occurred in 20% and 21% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with a sulfonylurea.”
  17. 17.
    FDA label (DailyMed): Trulicity prescribing information, section 7.1
    “TRULICITY delays gastric emptying and thus has the potential to reduce the rate of absorption of concomitantly administered oral medications.”
  18. 18.
    FDA label (DailyMed): Trulicity prescribing information, section 7.1
    “Monitor drug levels of oral medications with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with TRULICITY.”
  19. 19.
    FDA label (DailyMed): Trulicity prescribing information, section 14.2, Table 4
    “Table 4: Results at Week 26 in a Trial of TRULICITY as Monotherapy in Adult Patients with Type 2 Diabetes Mellitus. HbA1c (%) (Mean) - Change from baseline: TRULICITY 0.75 mg: -0.7; TRULICITY 1.5 mg: -0.8; Metformin 1500-2000 mg: -0.6”
  20. 20.
    FDA label (DailyMed): Trulicity prescribing information, section 14.3
    “At the 26-week placebo-controlled time point, the HbA1c change was 0.1%, -1.0%, -1.2%, and -0.6% for placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and sitagliptin, respectively.”
  21. 21.
    FDA label (DailyMed): Trulicity prescribing information, section 14.3
    “At 26 weeks, there was a mean weight reduction of 1.4 kg, 2.7 kg, 3.0 kg, and 1.4 kg for placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and sitagliptin, respectively.”
  22. 22.
    FDA label (DailyMed): Trulicity prescribing information, section 14.3, Table 6
    “Table 6. Results at Week 36 of TRULICITY 1.5 mg Compared to 3 mg and 4.5 mg as Add-On to Metformin in Adult Patients with Type 2 Diabetes Mellitus. HbA1c (%) (Mean) - Change from baseline: TRULICITY 1.5 mg: -1.5; TRULICITY 3 mg: -1.6; TRULICITY 4.5 mg: -1.8”
  23. 23.
    FDA label (DailyMed): Trulicity prescribing information, section 14.3, Table 6
    “Table 6. Results at Week 36 of TRULICITY 1.5 mg Compared to 3 mg and 4.5 mg as Add-On to Metformin in Adult Patients with Type 2 Diabetes Mellitus. Body Weight (kg) (Mean) - Change from baseline: TRULICITY 1.5 mg: -3.0; TRULICITY 3 mg: -3.8; TRULICITY 4.5 mg: -4.6”
  24. 24.
    FDA label (DailyMed): Trulicity prescribing information, section 14.5
    “TRULICITY significantly reduced the risk of first occurrence of primary composite endpoint of CV death, non-fatal MI, or non-fatal stroke (HR: 0.88, 95% CI 0.79, 0.99).”
  25. 25.
    FDA label (DailyMed): Trulicity prescribing information, section 5.6
    “TRULICITY is not recommended in patients with severe gastroparesis.”
  26. 26.
    FDA label (DailyMed): Trulicity prescribing information, section 8.4
    “The safety and effectiveness of TRULICITY have not been established in pediatric patients less than 10 years of age.”
  27. 27.
    FDA label (DailyMed): Trulicity prescribing information, section 8.7
    “However, there is limited clinical experience in patients with mild, moderate, or severe hepatic impairment; therefore, use TRULICITY with caution in these patient populations.”
  28. 28.
    FDA label (DailyMed): Trulicity prescribing information, section 4
    “TRULICITY is contraindicated in patients with: Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1)].”
  29. 29.
    FDA label (DailyMed): Trulicity prescribing information, section 4
    “TRULICITY is contraindicated in patients with: Serious hypersensitivity reaction to dulaglutide or to any of the product components.”
  30. 30.
    FDA label (DailyMed): Mounjaro prescribing information, section 14.6
    “Over a median follow-up of 210.1 weeks, MOUNJARO was non-inferior to dulaglutide for reducing the occurrence of MACE-3. The estimated hazard ratio for time to first MACE was 0.92 (95.3% CI: 0.83, 1.01) for MOUNJARO compared to dulaglutide. Superiority to dulaglutide was not established.”
  31. 31.
    CMS: Information for Part D Plans
    “Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
  32. 32.
  33. 33.
  34. 34.